Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
5
83%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 25 (83.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

NCT00345345
completedphase_2

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

NCT00069238
completedphase_2

Alemtuzumab to Treat Severe Aplastic Anemia

NCT00195624
completedphase_2

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

NCT00217594
completedphase_1

Campath in Chronic GVHD

NCT00495755
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00345345Phase 2

Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Completed
NCT00069238Phase 2

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Completed
NCT00195624Phase 2

Alemtuzumab to Treat Severe Aplastic Anemia

Completed
NCT00217594Phase 2

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Completed
NCT00495755Phase 1

Campath in Chronic GVHD

Completed
NCT00079768Phase 2

Alemtuzumab to Treat Sporadic Inclusion Body Myositis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6